Stocktoria
Janux Therapeutics, Inc. JANX
Janux Therapeutics, Inc. (JANX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $10.0M at a -1136.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | 2/9 | — | — | -5.6% |
| PRTA | PROTHENA CORP PUBLIC LTD CO | 1/9 | -5.98 | — | -92.8% |
| PGEN | PRECIGEN, INC. | 2/9 | — | — | — |
| CBIO | CRESCENT BIOPHARMA, INC. | 4/9 | 4.59 | — | — |
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
| ROIV | Roivant Sciences Ltd. | 1/9 | 18.07 | — | -71.6% |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
FAQ
Is JANX financially healthy?
Janux Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does JANX pay a dividend?
No, Janux Therapeutics, Inc. does not currently pay a dividend.
How profitable is JANX?
In FY2025, Janux Therapeutics, Inc. had a net margin of -1136.2% and a return on equity of -11.9%.
What is the analyst price target for JANX?
The average Wall-Street price target for Janux Therapeutics, Inc. is $37.19, about 123.1% above the recent price, from 16 analysts (consensus: strong buy).
Is JANX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Janux Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.